Page 934 - Clinical Immunology_ Principles and Practice ( PDFDrive )

902 Part Seven Organ-Specific Inflammatory Disease

double-blind, placebo-controlled trial. Lancet 2013;381(9884):2167–75. Neurol Neuroimmunol Neuroinflamm 2016;3(1):e194. PubMed PMID:
PubMed PMID: 23562009. eng. 26819963. Pubmed Central PMCID: 4723135.
47. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with 57. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon
relapsing multiple sclerosis after disease-modifying therapy: a randomised beta 1a as first-line treatment for patients with relapsing-remitting
controlled phase 3 trial. Lancet 2012;380(9856):1829–39. PubMed PMID: multiple sclerosis: a randomised controlled phase 3 trial. Lancet
23122650. eng. 2012;380(9856):1819–28. PubMed PMID: 23122652.
48. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting 58. Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after
multiple sclerosis: a systematic review and meta-analysis of the lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc
comparative trials. J Neurol Sci 2011;302(1-2):96–105. PubMed PMID: Natl Acad Sci USA 2013;110(50):20200–5. PubMed PMID: 24282306.
21167504. Pubmed Central PMCID: 3864306.
49. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse 59. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory
rate and improves disability in relapsing-remitting multiple sclerosis: CD56(bright) natural killer cells mediate immunomodulatory effects of
results of a phase III multicenter, double-blind placebo-controlled trial. IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl
The Copolymer 1 Multiple Sclerosis Study Group. Neurology Acad Sci USA 2006;103(15):5941–6. PubMed PMID: 16585503. Pubmed
1995;45(7):1268–76. PubMed PMID: 7617181. Epub 1995/07/01. eng. Central PMCID: 1458677.
50. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral 60. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25
teriflunomide for relapsing multiple sclerosis. N Engl J Med blockade is associated with decreased intrathecal inflammation in
2011;365(14):1293–303. PubMed PMID: 21991951. eng. multiple sclerosis. Sci Transl Med 2012;4(145):145ra06. PubMed PMID:
51. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus 22855463. Pubmed Central PMCID: 3846177.
subcutaneous interferon beta-1a in patients with relapsing multiple 61. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon
sclerosis: a randomised, controlled phase 3 trial. Mult Scler Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med
2014;20(6):705–16. PubMed PMID: 24126064. 2015;373(15):1418–28. PubMed PMID: 26444729.
52. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of 62. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab
oral BG-12 for relapsing multiple sclerosis. N Engl J Med in relapsing-remitting multiple sclerosis. N Engl J Med
2012;367(12):1098–107. PubMed PMID: 22992073. 2008;358(7):676–88. PubMed PMID: 18272891. eng.
53. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of 63. Sastre-Garriga J, Wiendl H. Highlights from the 31st ECTRIMS
oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med congress - Barcelona 2015. Mult Scler 2016;22(1):7–10. PubMed PMID:
2012;367(12):1087–97. PubMed PMID: 22992072. 26684283.
54. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral 64. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells
fingolimod in relapsing multiple sclerosis. N Engl J Med in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol
2010;362(5):387–401. PubMed PMID: 20089952. Epub 2010/01/22. eng. 2006;180(1-2):63–70. PubMed PMID: 16904756. Pubmed Central
55. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon PMCID: 1769354.
beta-1a for relapsing multiple sclerosis. N Engl J Med 65. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B
2006;354(9):911–23. PubMed PMID: 16510745. cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med
56. De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term 2015;7(310):310ra166. PubMed PMID: 26491076.
immunologic effect: Treg suppressor function increases up to 24 months.